"Today's announcement of the licensing of our Staccato nicotine technology to Cypress, along with our recently announced plans to advance AZ-007 (Staccato zaleplon) into Phase 2 clinical development, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results